|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
BioTime (BTX)'s Subsidiary OncoCyte Corporation Provides Update on PanC-DxTM, and Related Diagnostic Products
4/24/2012 8:42:13 AM
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE Amex: BTX) announced today that Joseph Wagner, Ph.D., the CEO of BioTime’s subsidiary OncoCyte Corporation and Karen B. Chapman, Ph.D., Director of Bioinformatics will provide updates on the development of the Company’s pan-cancer diagnostic PanC-DxTM and related diagnostics at an investor meeting in New York City. PanC-DxTM is a screening diagnostic that may permit the use of a blood test to screen patients for a number of solid cancer types such as those of the breast, colon, and lung. In his presentation, Dr. Wagner will describe the next-generation cancer diagnostics based on improved technologies in genomics and proteomics. He will also update investors on the planned development timeline of PanC-DxTM leading to an anticipated product launch in Europe in late 2014.
|
|
|
|
|
|
|
|
|
|
|